April 18, 2016 | News

Burlington Labs at Nat'l Rx Drug Abuse & Heroin Summit

By Tara Connolly | Burlington Labs Southern Regional Manager

Along with my colleague John Ryan, one of our local representatives in Georgia, I had the opportunity to represent Burlington Labs at the National Rx Drug Abuse and Heroin Summit in Atlanta at the end of March. Folks may recall that this conference garnered a tremendous amount of national media attention due to the fact that President Obama participated in one of the panel discussions.


John Ryan speaks with another conference attendee at the Burlington Labs booth.

I’ve attended many industry conferences, but this one definitely had a unique dynamic due to the high-profile attendees, which, along with the President, also included the Surgeon General, National Drug Policy Director Michael Botticelli, and several Congressional leaders. Just the amount of security precautions that need to be taken for a Presidential visit were fascinating to observe. The day of the visit, city buses were brought in to block all roads for a 1-block radius around the hotel. There was a 2-hour security sweep of all meeting rooms prior to the President’s speech. And people started lining up at 8 am to get a good seat for the President’s talk, which didn’t start until 2:30 pm that day.

Summit TuePM 299 a

President Obama participates in a panel discussion along with Americans in recovery. Photo Courtesy Operation UNITE.

Despite the crowds and the inconveniences, the buzz in the air was infectious. Regardless of people’s political affiliations, every conversation I had regarding the President’s visit was overwhelmingly positive. Everyone agreed that his visit would shine a light on the opioid epidemic, and his comments on the panel discussion with Americans in recovery were very well-received.

I’m honored that Burlington Labs was able to attend the Summit and be a part of this important national conversation about addiction, treatment and recovery.


This article appeared in the May/June edition of our newsletter, TheBuzz.